Insmed Inc (INSM) 10.84 $INSM
Insmed Down 14.4% Since SmarTrend Downtrend Call (INSM)
Comtex SmarTrend(R) - Wed Jun 29, 1:18AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on May 4th, 2016 at $11.36. In approximately 2 months, Insmed has returned 14.40% as of today's recent price of $9.72.
INSM: 10.84 (+0.09)
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Insmed, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Wed Jun 22, 4:45PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Insmed, Inc. ("Insmed" or the "Company"
(Nasdaq: INSM). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
INSM: 10.84 (+0.09)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Insmed Incorporated (INSM)
PR Newswire - Thu Jun 09, 9:53AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Insmed Incorporated ("Insmed" or the "Company" (NASDAQ: INSM). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst Yael Hurwitz at info@bgandg.com or 212-697-6484.
INSM: 10.84 (+0.09)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed, Inc. - INSM
PR Newswire - Wed Jun 08, 5:06PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Insmed, Inc. ("Insmed" or the Company) (NASDAQ: INSM). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
INSM: 10.84 (+0.09)
Insmed Announces Withdrawal of Marketing Authorization Application for ARIKAYCE(TM) in Europe
GlobeNewswire - Wed Jun 08, 3:30PM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for ARIKAYCE(TM) for the treatment of nontuberculous mycobacteria (NTM) lung disease.
INSM: 10.84 (+0.09)
Insmed to Present at the Bank of America Global Healthcare Conference
GlobeNewswire - Mon May 09, 7:00AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the Bank of America Global Healthcare Conference on Thursday May 12, 2016 in Las Vegas. Andy Drechsler, chief financial officer of Insmed, will deliver a corporate overview at 8:00 AM PT.
INSM: 10.84 (+0.09)
Insmed reports 1Q loss
Automated Insights - Thu May 05, 2:27PM CDT
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $33.5 million in its first quarter.
INSM: 10.84 (+0.09)
Insmed Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:03AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the quarter ended March 31, 2016.
INSM: 10.84 (+0.09)
Insmed Announces Upcoming Presentations at the American Thoracic Society 2016 International Meeting
GlobeNewswire - Tue May 03, 7:00AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that three ARIKAYCE(TM)-related abstracts and one treprostinil prodrug abstract were accepted for presentation at the American Thoracic Society (ATS) 2016 International Conference taking place in San Francisco May 13 to 18. ARIKAYCE, or liposomal amikacin for inhalation, is in late-stage development for the treatment of adult patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The company's earlier-stage pipeline includes a number of treprostinil prodrugs, which may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma.
INSM: 10.84 (+0.09)
Shares of INSM Down 21.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 3 months, Insmed has returned 21.06% as of today's recent price of $12.67.
INSM: 10.84 (+0.09)
Downtrend Call Working As Insmed Stock Falls 26.8% (INSM)
Comtex SmarTrend(R) - Thu Mar 24, 12:37PM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 3 months, Insmed has returned 26.79% as of today's recent price of $11.75.
INSM: 10.84 (+0.09)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 10.84 (+0.09), PFE: 36.29 (+0.17), OMER: 11.78 (+0.19), ICPT: 152.30 (+0.57), ABBV: 64.75 (+0.59), IONS: 25.68 (+0.32), NVS: 82.54 (+0.41)
24.2% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Mon Feb 08, 11:55AM CST
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 1 month, Insmed has returned 24.17% as of today's recent price of $12.17.
INSM: 10.84 (+0.09)
Insmed Shares Down 24.2% Since SmarTrend's Sell Call (INSM)
Comtex SmarTrend(R) - Mon Feb 08, 11:34AM CST
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 1 month, Insmed has returned 24.17% as of today's recent price of $12.17.
INSM: 10.84 (+0.09)
BUYINS.NET: INSM, ED, TWMC, FRME, KEM, DWCH, Expected to Trade Higher After Bullish Insider Trading
M2 - Thu Feb 04, 8:50AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Insmed Inc (NASDAQ:INSM), Consolidated Edison Inc (NYSE:ED), Trans World Entertainment Corp (NASDAQ:TWMC), FIRST MERCHANTS CORPORATION (NASDAQ:FRME), KEMET Corp (NYSE:KEM), Datawatch Corp (NASDAQ
WCH) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
INSM: 10.84 (+0.09), TWMC: 3.55 (-0.16), KEM: 3.01 (+0.07), ED: 80.20 (-0.18), FRME: 24.91 (+0.19), DWCH: 5.85 (-0.07)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.84 (+0.09), VRTX: 90.61 (+1.65), PFE: 36.29 (+0.17), GSK: 43.66 (+0.28), CNCE: 11.97 (+0.17), GLPG: 55.25 (+0.02), CYCC: 5.01 (-0.01), PTI: 12.42 (+0.56), SHPG: 187.37 (-0.84), PULM: 2.11 (+0.03), MRK: 59.55 (+0.20), NVLS: 4.75 (+0.13), PTCT: 7.52 (-0.01), KMDA: 3.70 (+0.07), AKTX: 11.18 (-0.85), NVS: 82.54 (+0.41)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.84 (+0.09), CYCC: 5.01 (-0.01), HZNP: 19.22 (+0.51), KMDA: 3.70 (+0.07), GSK: 43.66 (+0.28), AKTX: 11.18 (-0.85), APHB: 1.60 (+0.02), CNCE: 11.97 (+0.17), GLPG: 55.25 (+0.02)
Insmed Down 14.4% Since SmarTrend Downtrend Call (INSM)
Comtex SmarTrend(R) - Wed Jun 29, 1:18AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on May 4th, 2016 at $11.36. In approximately 2 months, Insmed has returned 14.40% as of today's recent price of $9.72.
INSM: 10.84 (+0.09)
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Insmed, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Wed Jun 22, 4:45PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Insmed, Inc. ("Insmed" or the "Company"
(Nasdaq: INSM). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. INSM: 10.84 (+0.09)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Insmed Incorporated (INSM)
PR Newswire - Thu Jun 09, 9:53AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Insmed Incorporated ("Insmed" or the "Company"
(NASDAQ: INSM). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst Yael Hurwitz at info@bgandg.com or 212-697-6484. INSM: 10.84 (+0.09)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed, Inc. - INSM
PR Newswire - Wed Jun 08, 5:06PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Insmed, Inc. ("Insmed" or the Company) (NASDAQ: INSM). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
INSM: 10.84 (+0.09)
Insmed Announces Withdrawal of Marketing Authorization Application for ARIKAYCE(TM) in Europe
GlobeNewswire - Wed Jun 08, 3:30PM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for ARIKAYCE(TM) for the treatment of nontuberculous mycobacteria (NTM) lung disease.
INSM: 10.84 (+0.09)
Insmed to Present at the Bank of America Global Healthcare Conference
GlobeNewswire - Mon May 09, 7:00AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that company management will participate at the Bank of America Global Healthcare Conference on Thursday May 12, 2016 in Las Vegas. Andy Drechsler, chief financial officer of Insmed, will deliver a corporate overview at 8:00 AM PT.
INSM: 10.84 (+0.09)
Insmed reports 1Q loss
Automated Insights - Thu May 05, 2:27PM CDT
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $33.5 million in its first quarter.
INSM: 10.84 (+0.09)
Insmed Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:03AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the quarter ended March 31, 2016.
INSM: 10.84 (+0.09)
Insmed Announces Upcoming Presentations at the American Thoracic Society 2016 International Meeting
GlobeNewswire - Tue May 03, 7:00AM CDT
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that three ARIKAYCE(TM)-related abstracts and one treprostinil prodrug abstract were accepted for presentation at the American Thoracic Society (ATS) 2016 International Conference taking place in San Francisco May 13 to 18. ARIKAYCE, or liposomal amikacin for inhalation, is in late-stage development for the treatment of adult patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The company's earlier-stage pipeline includes a number of treprostinil prodrugs, which may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma.
INSM: 10.84 (+0.09)
Shares of INSM Down 21.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 3 months, Insmed has returned 21.06% as of today's recent price of $12.67.
INSM: 10.84 (+0.09)
Downtrend Call Working As Insmed Stock Falls 26.8% (INSM)
Comtex SmarTrend(R) - Thu Mar 24, 12:37PM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 3 months, Insmed has returned 26.79% as of today's recent price of $11.75.
INSM: 10.84 (+0.09)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 10.84 (+0.09), PFE: 36.29 (+0.17), OMER: 11.78 (+0.19), ICPT: 152.30 (+0.57), ABBV: 64.75 (+0.59), IONS: 25.68 (+0.32), NVS: 82.54 (+0.41)
24.2% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Mon Feb 08, 11:55AM CST
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 1 month, Insmed has returned 24.17% as of today's recent price of $12.17.
INSM: 10.84 (+0.09)
Insmed Shares Down 24.2% Since SmarTrend's Sell Call (INSM)
Comtex SmarTrend(R) - Mon Feb 08, 11:34AM CST
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on January 7th, 2016 at $16.05. In approximately 1 month, Insmed has returned 24.17% as of today's recent price of $12.17.
INSM: 10.84 (+0.09)
BUYINS.NET: INSM, ED, TWMC, FRME, KEM, DWCH, Expected to Trade Higher After Bullish Insider Trading
M2 - Thu Feb 04, 8:50AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Insmed Inc (NASDAQ:INSM), Consolidated Edison Inc (NYSE:ED), Trans World Entertainment Corp (NASDAQ:TWMC), FIRST MERCHANTS CORPORATION (NASDAQ:FRME), KEMET Corp (NYSE:KEM), Datawatch Corp (NASDAQ
WCH) are all expected to go Higher as Buy signals have been generated by top insider trading patterns. INSM: 10.84 (+0.09), TWMC: 3.55 (-0.16), KEM: 3.01 (+0.07), ED: 80.20 (-0.18), FRME: 24.91 (+0.19), DWCH: 5.85 (-0.07)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.84 (+0.09), VRTX: 90.61 (+1.65), PFE: 36.29 (+0.17), GSK: 43.66 (+0.28), CNCE: 11.97 (+0.17), GLPG: 55.25 (+0.02), CYCC: 5.01 (-0.01), PTI: 12.42 (+0.56), SHPG: 187.37 (-0.84), PULM: 2.11 (+0.03), MRK: 59.55 (+0.20), NVLS: 4.75 (+0.13), PTCT: 7.52 (-0.01), KMDA: 3.70 (+0.07), AKTX: 11.18 (-0.85), NVS: 82.54 (+0.41)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.84 (+0.09), CYCC: 5.01 (-0.01), HZNP: 19.22 (+0.51), KMDA: 3.70 (+0.07), GSK: 43.66 (+0.28), AKTX: 11.18 (-0.85), APHB: 1.60 (+0.02), CNCE: 11.97 (+0.17), GLPG: 55.25 (+0.02)
